
Merck licenses Portola's betrixaban; returns rights
Executive Summary
Portola Pharmaceuticals (cardiovascular diseases, inflammatory conditions, and cancer) has granted Merck exclusive worldwide development and commercialization rights to its Phase II anticoagulant betrixaban.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- Co-Promotion
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com